About AVEO

AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The company is focused on developing and commercializing its lead candidate tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, in North America as a treatment for renal cell carcinoma and other cancers. AVEO is leveraging multiple partnerships to develop and commercialize tivozanib in non-oncologic indications worldwide and oncology indications outside of North America, as well as to progress its pipeline of novel therapeutic candidates in cancer and cachexia (wasting syndrome).
Primary Exchange: NASDAQ
SIC Pharmaceutical Preparations
NAICS Pharmaceutical Preparation Manufacturing

AVEO is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
URTY ProShares UltraPro Russell2000 104.2 M 1.04202E+08 2,017 2017 0.0% 7.24688E-06 2 K 2445
UWM ProShares Ultra Russell2000 182.3 M 1.82294E+08 2,017 2017 0.0% 1.08488E-05 4 K 4388
VTWG Vanguard Russell 2000 Growth ETF 286.3 M 2.863E+08 1,245 1245 0.0% 3E-05 9 K 8894
VXF Vanguard Extended Market ETF 6.8 B 6.8E+09 3,242 3242 0.0% 1E-05 86 K 86299
ONEQ Fidelity Nasdaq Composite Index Tracking Stock 2.0 B 2E+09 1,004 1004 0.0% 4.78446E-05 94 K 93693
ITOT iShares Core S&P Total U.S. Stock Market ETF 18.6 B 1.85536E+10 3,550 3550 0.0% 0 23 K 23345
IWC iShares Microcap ETF 914.4 M 9.14374E+08 1,451 1451 0.02% 0.0002 155 K 154589
IWM iShares Russell 2000 ETF 43.0 B 4.29906E+10 2,006 2006 0.0% 0 1.3 M 1298640
IWN iShares Russell 2000 Value ETF 9.2 B 9.24826E+09 1,370 1370 0.0% 0 242 K 241568
IWO iShares Russell 2000 Growth ETF 9.1 B 9.14116E+09 1,239 1239 0.0% 0 313 K 313313
IWV iShares Russell 3000 ETF 9.8 B 9.77316E+09 2,956 2956 0.0% 0 24 K 23871

Wait, Before You Leave...